The Chinese team found that antibodies that block new crown infection could help vaccine development

category:Global
 The Chinese team found that antibodies that block new crown infection could help vaccine development


Several units, including Capital Medical University of China, Institute of Microbiology, Chinese Academy of Sciences, Tianjin Institute of industrial biotechnology, Chinese Academy of Sciences and Shenzhen Third Peoples Hospital, participated in the study. The researchers isolated four human monoclonal antibodies from peripheral blood monocytes of a new crown rehabilitation patient. The novel coronavirus has neutralization ability by these 4 antibodies. Among them, two kinds of antibodies, b38 and H4, can block the binding of the receptor binding domain of CNV spike protein and its receptor ACE2.

(function() {(window. Slotbydup = window. Slotbydup| []). Push ({ID: u5811557, container: ssp_, async: true});)) (); previous studies have revealed the mechanism of infection of new coronavirus, indicating that the virus is mainly infected by the combination of its surface spike protein receptor domain and ACE2 on human cells. Experiments show that b38 and H4 recognize different epitopes of receptor binding domain respectively, and mouse experiments confirm that these two antibodies can reduce the amount of virus in the lungs of infected mice, showing the therapeutic effect. The two antibodies can also be mixed to inhibit virus infection more effectively. The team further analyzed the structure of the complex formed by the receptor binding region of CNV spike protein and b38, thus revealing the molecular mechanism of b38 blocking virus infection. The latest research shows that the two antibodies have the potential to be further developed into drugs for the treatment of new coronavirus infection, and provide a basis for vaccine design, the researchers said. At present, the two antibodies have been transformed in related companies and are expected to be used in the clinical treatment of new crown patients in the future. (end) source: Xinhua News Agency Author: Peng Xi editor in charge: Sheng Yuqing, nbjs10200

A number of previous studies have revealed the infection mechanism of the new coronavirus, indicating that the virus is mainly infected by binding its surface spike protein receptor domain to ACE2 on human cells. Experiments show that b38 and H4 recognize different epitopes of receptor binding domain respectively, and mouse experiments confirm that these two antibodies can reduce the amount of virus in the lungs of infected mice, showing the therapeutic effect. The two antibodies can also be mixed to inhibit virus infection more effectively.

The team further analyzed the structure of the complex formed by the receptor binding region of CNV spike protein and b38, thus revealing the molecular mechanism of b38 blocking virus infection.

The latest research shows that the two antibodies have the potential to be further developed into drugs for the treatment of new coronavirus infection, and provide a basis for vaccine design, the researchers said. At present, the two antibodies have been transformed in related companies and are expected to be used in the clinical treatment of new crown patients in the future. (end)